Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Lovell

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Bulletin of the NYU Hospital for Joint Diseases|November 24, 2006
Update on treatment of arthritis in children: new treatments, new goalsDaniel J Lovell
Annals of the Rheumatic Diseases|June 8, 2010
Juvenile idiopathic arthritis: state of the art and future perspectivesAlberto Martini, Daniel J Lovell
Nature Clinical Practice. Rheumatology|September 5, 2006
Comparison of treatment-response criteria for juvenile idiopathic arthritisOlcay Y Jones, Daniel J Lovell
Current Opinion in Rheumatology|April 20, 2005
Pediatric clinical researchDaniel J Lovell, Natasha M Ruth
Best Practice & Research. Clinical Rheumatology|October 22, 2002
Advanced therapy for juvenile arthritisKevin J Murray, Daniel J Lovell
Arthritis Care & Research|December 17, 2020
Evolution in the Understanding of Pediatric-Onset Axial SpondyloarthritisDaniel J Lovell, Hermine I Brunner
Nature Clinical Practice. Rheumatology|May 22, 2008
Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis?Tracy V Ting, Daniel J Lovell
Clinical Immunology (Orlando, Fla.)|September 29, 2004
Immunosuppressants, infection, and inflammationDaniel J Lovell, Theoklis E Zaoutis, Kathleen Sullivan
Arthritis and Rheumatism|April 9, 2005
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory diseaseDaniel J Lovell, Suzanne L Bowyer, Alan M Solinger
Annals of the Rheumatic Diseases|September 21, 2018
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunitiesHermine I Brunner, Alberto Martini, Daniel J Lovell, et al.
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Bulletin of the NYU Hospital for Joint Diseases|November 24, 2006
Update on treatment of arthritis in children: new treatments, new goalsDaniel J Lovell
Annals of the Rheumatic Diseases|June 8, 2010
Juvenile idiopathic arthritis: state of the art and future perspectivesAlberto Martini, Daniel J Lovell
Nature Clinical Practice. Rheumatology|September 5, 2006
Comparison of treatment-response criteria for juvenile idiopathic arthritisOlcay Y Jones, Daniel J Lovell
Current Opinion in Rheumatology|April 20, 2005
Pediatric clinical researchDaniel J Lovell, Natasha M Ruth
Best Practice & Research. Clinical Rheumatology|October 22, 2002
Advanced therapy for juvenile arthritisKevin J Murray, Daniel J Lovell
Arthritis Care & Research|December 17, 2020
Evolution in the Understanding of Pediatric-Onset Axial SpondyloarthritisDaniel J Lovell, Hermine I Brunner
Nature Clinical Practice. Rheumatology|May 22, 2008
Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis?Tracy V Ting, Daniel J Lovell
Clinical Immunology (Orlando, Fla.)|September 29, 2004
Immunosuppressants, infection, and inflammationDaniel J Lovell, Theoklis E Zaoutis, Kathleen Sullivan
Arthritis and Rheumatism|April 9, 2005
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory diseaseDaniel J Lovell, Suzanne L Bowyer, Alan M Solinger
Annals of the Rheumatic Diseases|September 21, 2018
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunitiesHermine I Brunner, Alberto Martini, Daniel J Lovell, et al.
Pageof 17